Methylprednisolone

Abstract

Hypertension and hepatitis-B virus reactivation: 2 case reportsIn a prospective study of 30 patients with seronegative Hepatitis-B virus-associated glomerulonephritis (sn HBV-GN), two patients including one woman [ages not stated; not all sexes stated] were described, who developed new-onset hypertension or HBV reactivation during treatment with methylprednisolone [time to reaction onset not stated; not all outcomes stated].The patient, with sn HBV-GN and nephrotic syndrome, started receiving oral methylprednisolone 0.8 mg/kg/day for 12-24 weeks. However, the patient developed new-onset hypertension secondary to methylprednisolone.The woman, with sn HBV-GN and proteinuria, started receiving oral methylprednisolone 0.8 mg/kg/day for 12-24 weeks. However, she exhibited HBV DNA positivity during the treatment. Two months after methylprednisolone therapy, HBV DNA level was 1.14 X 10 3 IU/mL, suggestive of HBV reactivation. Therefore, she started receiving lamivudine with methylprednisolone. After 1 month, her serum HBV DNA level became undetectable.